title: Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.
abstract: Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout. In addition, there is growing evidence of an association between high serum levels of uric acid (sUA) and cardiovascular disease (CVD). In this preliminary report, we present 12-16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD. Febuxostat titrated from 10 mg/day up to 40 mg/day resulted in statistically significant and clinically relevant reductions in sUA after 12-16 weeks. A "responder" level of 6.0 mg/dL or lower was achieved in 95 of 100 (95%) patients. Significant reductions in sUA were achieved regardless of the presence/absence of coexisting diseases (e.g. CVD, renal insufficiency, diabetes and obesity) or the class of antihypertensive agent being used by the patient. No serious adverse reactions were noted with febuxostat. Although allopurinol has been used generally for hyperuricemia/gout, it is excreted fully via the kidneys, restricting its use in patients with reduced renal function, and its three-times-daily administration leads to poor adherence. Based on the results of this study, febuxostat may provide an easier option than allopurinol for clinicians specializing in CVDs.
authors.affiliation: Hiramitsu Heart Clinic , Nagoya , Japan .
authors.forename: Shinya
authors.initials: S
authors.lastname: Hiramitsu
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishiguro
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Matsuyama
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamada
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kato
authors.forename: Manji
authors.initials: M
authors.lastname: Noba
authors.forename: Akihisa
authors.initials: A
authors.lastname: Uemura
authors.forename: Yoshirou
authors.initials: Y
authors.lastname: Matsubara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoshida
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kani
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tokuda
authors.forename: Hisashi
authors.initials: H
authors.lastname: Kato
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Tatsushi
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Shiro
authors.initials: S
authors.lastname: Matsubara
authors.forename: Kazuma
authors.initials: K
authors.lastname: Mori
authors.forename: Hisashi
authors.initials: H
authors.lastname: Kimura
authors.forename: Kenji
authors.initials: K
authors.lastname: Shino
authors.forename: Yasuchika
authors.initials: Y
authors.lastname: Kato
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishii
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D000069465:Febuxostat; D005260:Female; D006074:Gout Suppressants / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood / Q000652:urine
chemical_list: D006074:Gout Suppressants; D013844:Thiazoles; D000069465:Febuxostat; D014527:Uric Acid
keywords: Allopurinol; blood pressure; cardiovascular risk; febuxostat; gout; hyperuricemia